Literature DB >> 19894141

Close cardiac surveillance of patients treated with anthracyclines, also necessary after chemotherapy?

Leo H B Baur.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19894141     DOI: 10.1007/s10554-009-9525-3

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


× No keyword cloud information.
  8 in total

1.  Anthracycline cardiotoxicity in children.

Authors:  Leontine C M Kremer; Huib N Caron
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

2.  Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.

Authors:  H Matsui; I Morishima; Y Numaguchi; Y Toki; K Okumura; T Hayakawa
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 3.  Exposure to anthracyclines during childhood causes cardiac injury.

Authors:  Steven E Lipshultz
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

Review 4.  Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.

Authors:  Benny Vittrup Jensen
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

5.  Effects by doxorubicin on the myocardium are mediated by oxygen free radicals.

Authors:  M F Xu; P L Tang; Z M Qian; M Ashraf
Journal:  Life Sci       Date:  2001-01-12       Impact factor: 5.037

Review 6.  New developments in anthracycline-induced cardiotoxicity.

Authors:  A Mordente; E Meucci; A Silvestrini; G E Martorana; B Giardina
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Authors:  Jon M Appel; Benny V Jensen; Dorte L Nielsen; Marianne Ryberg; Bo Zerahn
Journal:  Int J Cardiovasc Imaging       Date:  2009-10-13       Impact factor: 2.357

8.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.